Ann: PromarkerD latest results published in peer reviewed journal, page-14

Scratchback, the announcement, IMO, is probably one of the most important announcements this company has ever made (obviously following announcements validating the PromarkerD diagnostic platform).

To put it in simple terms, the announcement is significant because it allows the globalmass production and use of PromarkerD, subject to regulatory approval as Richard mentions. The mass production and use of PromarkerD is critical to allow PIQ bring in significant revenue, and is key for PIQ becoming the global leader of diagnostics (currently for DKD only, but possibly for many other diseases in the future).

The reason PromarkerD can now be mass produced is because the IVD uses Immunoassay technology and does not rely on mass spectrometry to quantify the chemical data. I have provided a brief summary/overview of each analysis technique - you be the judge on how significant this announcement is.....

Mass Spectrometry Analysis - This method relies on the sample being sent through a mass spectrometry unit. Only a select number of laboratories have Mass Spectrometry Units - these can cost up to $1m to purchase (and possibly more, depending on the capacity of the unit). Mass and global rollout utilising this method is unlikely, and significant revenues is less likely utilising this method IMO. Provided below is a picture of a mass spectrometer FYI.



Immunoassay Analysis (in our case specifically - ELISA) - a known antigen is attached to a solid surface. A solution containing the patient sample is added. If the patient's sample contains antibody, it will bind to the antigen. A second antibody (against human antibodies) that is labeled with an enzyme is then added. If the enzyme-linked antibody binds to human antibodies, the enzyme will create a detectable change that indicates the presence and amount of the antibody in the patient sample. Below is a picture of ELISA in action. These IVD "kits" can be utilised by laboratories without the need of a mass spec unit. Global rollout using the IVD is far more likely than utilising mass spectrometry, since the "target market" of laboratories is MUCH GREATER (i.e. you don't need to fork out the cash to buy a mass spec unit).



Sure you can sell for a quick 10% to 20% profit (a profit is a profit right), and this is clearly what has occurred today... BUT IMO it is purely because the sellers do not understand the significance of this announcement. For me personally, I have stocks which I sell for pip profits, and stocks which I keep for capital growth and future dividends. PIQ is the former for me, particularly given today's announcement...